Commentary

SARS-CoV-2 vaccination for immune-compromised patients: More is required

Hui Li a, b, c, Jiapei Yu d, Bin Cao a, b, c, d, * 

a Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China 
b Department of Respiratory Medicine, Capital Medical University, Beijing, China 
c Institute of Respiratory Medicine, Chinese Academy of Medical Science, Beijing, China 
d Tsinghua University–Peking University Joint Center for Life Sciences, Beijing, China

The two-dose BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) are among the common used vaccines against SARS-CoV-2, with the estimated effectiveness for preventing COVID-19 after the second dose above 90% [1,2]. Immune-compromised populations, including solid-organ transplant recipients are typically excluded from trials investigating COVID-19 vaccines, though they are at increased risk for severe SARS-CoV-2 infection [3,4].

It is gratifying that Julian et al provided a comprehensive understanding of both humoral and cellular immune response after vaccination with the BNT162b2 and mRNA-1273 in dialysis patients and kidney transplant recipients (KTR) in this Issue of The Lancet Regional Health – Europe [5]. Seroconversion was tested with the SARS-CoV-2 NeutralLISA and the level of cellular immunity level was evaluated by the interferon-γ release assay or flow cytometry. They revealed that compared with a relatively healthy population, the seroconversion and cell-mediated immunity induced by the SARS-CoV-2 vaccine in KRTs are at a much lower level. However, the immunological efficacy of the SARS-CoV-2 mRNA vaccine in the dialysis patients were only slightly influenced. Meanwhile, they suggested that the poor efficacy of the SARS-CoV-2 vaccine in KRTs might be influenced by type and number of immunosuppressive drugs as well as the vaccine types [5]. The results are consistent with Boyarsky’s recent finding that only 54% of the solid organ recipients showed detectable antibodies even after the second dose of mRNA SARS-CoV-2 vaccine and those receiving antimitobalities showed even worse antibody response [6].

But there are still quite a lot of problems waiting to be solved regarding to the vaccination against COVID-19 among immunodeficiency population. First, in addition to CD4+ T cells, CD8+ T cells also play a significant role in the defense and activation of immune response post-vaccination, and the longitudinal variation and detailed features of CD8+ T-cell response remain uncertain. Second, the vaccination-related seroconversion of antibody or T cell immune response doesn’t equal to sufficient immune protection against subsequent infection [7]. In the study, though capacity against infection of the two vaccines in KRTs was assessed, no concrete conclusion could be drawn due to the limitation of sample size and short follow-up time. In a recent real-world study, the effectiveness of the BNT162b2 mRNA vaccine in immunodeficiency people including solid organ recipients is indeed lower than in healthy population, with 90% against documented infection and 84% against symptomatic infection [8]. However, the immunodeficiency population includes a large group of heterogeneous populations, and future research needs to be further refined and stratified.

Though with limitation, all these data hint that the effectiveness of SARS-CoV-2 mRNA vaccine was comprised in immunodeficiency population and the standard two-dose mRNA vaccine was not able to provide enough protection. It is encouraging to try additional booster dose of vaccine to improve COVID-19 vaccine responses in immunodeficiency population. In a recent case series, 30 solid organ recipients who had a suboptimal response to standard vaccination were given a third dose of vaccine. Antibody titers increased after the third dose in one-third of patients with negative antibody titers or low-positive antibody titers [9]. The scientific problem of whether additional dose will increase the vaccination-related immune response and improve the clinical effectiveness still needs to be verified by large-scale clinical trial. Further, we also need to investigate the duration of the immunological memory to SARS-CoV-2 after vaccination and its association with host’s immune status.

In addition to efficacy, the safety of vaccines should not be ignored. Julian et al found hospitalization due to vaccination happened to 1.6% (6/376) of the KTRs and 0.4% ((5/1304) of the dialysis people. Whether the mRNA vaccine is safe in the immunodeficiency still needs further investigation, especially in the cases that potentially require additional vaccination. It has been suggested that systemic events such as fever, fatigue, headache, chills, were more often after receiving the second dose of either the BNT162b2 or mRNA-
1273 vaccine than after receiving the first dose [1,2]. If immunodeficiency patients need to be vaccinated with a larger or additional dose of vaccine to obtain immune protection, caution should be taken that the side effects might increase extremely. Further large randomized controlled trials and real world studies are needed to validate the effectiveness and safety of additional booster dose of vaccine in the immunodeficiency patients.

In conclusion, immunodeficiency patients including solid organ recipients are at higher risk of severe or critical COVID-19 and they are the main targets needing vaccine protection. However, the standard two-dose mRNA vaccine was not able to provide them sufficient protection. More data is required to revise the vaccination policy in these patients.

Contributors

Hui Li, Jiapei Yu and Bin Cao drafted the comments together.

Declaration of Interests

No potential conflict of interest exists for all the authors.

References

[1] Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020;383(27):2603–15.
[2] Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384(5):403–16.
[3] Shields AM, Burns SO, Savic S, Richter AG. COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience. J Allergy Clin Immunol 2021;147(3):870-875 e871.
[4] Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant 2020;20(7):1800–8.
[5] Julian STS, Tom L, Claudia K, et al. Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg Health Eur 2021. doi:10.1016/j.lanepe.2021.100178.
[6] Boyarsky BJ, Werbel WA, Avery RK, Tobias AAR, Massie AB, Seger DL, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 2021;325(21):2204–6.
[7] Hodgson SH, Mansatta K, Mallett G, et al. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis 2021;21(2):e26–35.
[8] Barda N, Dagan N, Balicer RD. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. Reply. N Engl J Med 2021;384(20):1970.
[9] Werbel WA, Boyarsky BJ, Ou MT, et al. Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Ann Intern Med 2021. doi:10.7326/l21-0282.